TSL.L Regulatory News (TSL)

6 Jul 2007 14:25

Tissue Science Laboratories PLC06 July 2007 6 July 2007 Tissue Science Laboratories plc Result of Annual General Meeting Tissue Science Laboratories plc, the medical technology company specialising inbiologic tissue replacement and repair products, held its Annual General Meetingtoday at which all resolutions were passed. -Ends- Enquiries: TSL plc Tel: 01252 333 002Martin Hunt, Chief Executive OfficerDavid Jennings, Finance Director Nomura Code Securities Tel: 0207 776 1200Juliet Thompson / Clare Terlouw Hogarth PR Tel: 020 7357 9477Melanie Toyne Sewell / Sarah Richardson Notes to Editors Background on TSL Tissue Science Laboratories plc is a medical technology company specialising intissue repair and replacement. Headquartered in Aldershot, Hampshire, TSLfloated in November 2001 and is listed on AIM (AIM: TSL). TSL has a proprietary sheet product, derived from porcine dermis, calledPermacol(R). The Permacol(R) sheet product has been developed with a range ofunique properties to make it suitable for use in different applications,including urology/gynaecology, complex and recurrent hernia repair, shoulderrotator cuff repair and head and face repair and reconstruction. TSL sellsPermacol(R) directly in the complex and recurrent hernia surgical field and hassigned distribution agreements with CR Bard Inc (urology/gynaecology -worldwide) and Zimmer Inc (orthopaedic - worldwide). Different formulations of Permacol(R) have also been developed successfully,including an injectable version, based on the same core technology. In addition,TSL has built a development pipeline derived from other porcine tissues e.g.bone, ligament and vascular that addresses the large and fast growing surgicalimplant market. This information is provided by RNS The company news service from the London Stock Exchange